DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Summary for Patent: 5,545,405
|Title:||Method for treating a mammal suffering from cancer with a cho-glycosylated antibody|
|Abstract:||The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.|
|Inventor(s):||Page; Martin J. (Beckenham, GB)|
|Assignee:||Burroughs Wellcome Co. (Research Triangle Park, NC)|
|Patent Claims:||1. In a method for treating a human suffering from cancer by administering a therapeutically effective amount of a whole glycosylated recombinant human, chimeric, CDR grafted or
bispecific antibody effective in treating said cancer, wherein the improvement comprises an antibody glycosylated by a Chinese hamster ovary cell.
2. A method in accordance with claim 1, wherein the cancer is non-Hodgkins lymphoma.
3. A method in accordance with claim 1, wherein the cancer is multiple myeloma.
4. A method in accordance with claim 3, wherein the antibody specifically recognizes a T cell marker.
5. A method in accordance with claim 4, wherein the antibody is an anti-CDw52 antibody.
6. A method in accordance with claim 1, wherein the antibody specifically recognizes a cancer cell marker antigen.
7. A method in accordance with claim 6, wherein the antibody is an anti-CD33 antibody or an anti-CD38 antibody.
8. A method in accordance with claim 1, wherein the antibody is administered in a daily dose of about 1 mg to about 10 mg.
9. A method in accordance with claim 1, wherein the antibody is administered for a period of about 1 to about 30 days.
Summary for Patent: Start Trial
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9022543||Oct 17, 1990|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genzyme||CAMPATH||alemtuzumab||VIAL; INTRAVENOUS||103948||001||2001-05-07||Start Trial||Burroughs Wellcome Co. (Research Triangle Park, NC)||2013-08-13||RX||Orphan||company|
|Genzyme||CAMPATH||alemtuzumab||VIAL; INTRAVENOUS||103948||002||2001-05-07||Start Trial||Burroughs Wellcome Co. (Research Triangle Park, NC)||2013-08-13||RX||Orphan||company|
|Genzyme||LEMTRADA||alemtuzumab||INJECTABLE;INJECTION||103948||003||2001-05-07||Start Trial||Burroughs Wellcome Co. (Research Triangle Park, NC)||2013-08-13||RX||Orphan||company|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|South Africa||9108248||Apr 16, 1993|
|United States of America||2002182208||Dec 05, 2002|
|United States of America||2003035799||Feb 20, 2003|
|United States of America||2004228857||Nov 18, 2004|
|United States of America||2008279852||Nov 13, 2008|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.